Detection of polyomavirus microRNA-5p expression in saliva shortly after kidney transplantation

Figures & data

Table 1. Demographic and clinical characteristics of study patients

Patient^a				TYPE OF	TIME OF	TYPE OF		CMV IgG
ID	SEX	AGE	DIALYSIS	DIALYSIS	DIALYSIS (Mo)	DONOR	RELATIONSHIP	RECEPTOR	DONOR		DISEASE		COMORBIDITIES
1	F	32	YES	DIALYSIS	11	DEAD	none	+	+		HYPERTENSION		YES
4	F	41	YES	HEMODIALYSIS	15	DEAD	none	+	+		ALPORT SYNDROME		NO
6	M	42	YES	HEMODIALYSIS	58	DEAD	none	+	+		HYPERTENSION		YES
7	M	24	YES	HEMODIALYSIS	7	ALIVE	FATHER/ MOTHER	+	+		GLOMERULONEPHRITIS		NO
9	F	34	YES	DIALYSIS	18	ALIVE	FATHER/ MOTHER	+	+		DIABETES MELLITUS		YES
10	M	38	YES	HEMODIALYSIS	25	ALIVE	WIFE	+	+		HYPERTENSION		YES
11	F	39	NO	Na		ALIVE	FATHER/ MOTHER	+	+		NEPHROPATHY OF IgA		YES
12	F	49	YES	HEMODIALYSIS	75	DEAD	none	+	+		POLYCYSTIC KIDNEY		NO
13	F	46	YES	HEMODIALYSIS	12	ALIVE	BROTHER	+	+		GLOMERULONEPHRITIS		YES
14	M	20	YES	HEMODIALYSIS	46	ALIVE	FATHER/ MOTHER	+	-		GESF		YES
15	F	29	YES	DIALYSIS	6	ALIVE	FATHER/ MOTHER	+	ND		GESF		YES
16	M	47	YES	HEMODIALYSIS	35	DEAD	none	+	+		ANTI-INFLAMMATORY DRUG USE		YES
18	M	47	YES	HEMODIALYSIS	73	ALIVE	COUSIN	+	ND		ALPORT SYNDROME		NO
19	M	69	YES	HEMODIALYSIS	18	DEAD	none	+	ND		HYPERTENSION		YES
20	M	30	NO	Na		ALIVE	FATHER/ MOTHER	+	ND		ONE KIDNEY		YES
21	F	50	YES	HEMODIALYSIS	27	ALIVE	BROTHER	+	+		UNKNOWN		YES
23	F	66	YES	HEMODIALYSIS	15	DEAD	none	+	ND		HYPERTENSION		YES
24	M	61	YES	HEMODIALYSIS	23	DEAD	none	-	ND		POLYCYSTIC KIDNEY		NO
25	F	53	YES	HEMODIALYSIS	48	DEAD	none	+	ND		POLYCYSTIC KIDNEY		NO
29	F	35	YES	HEMODIALYSIS	9	ALIVE	BROTHER	+	+		UNKNOWN		YES
30	M	19	NO	Na		ALIVE	GRANDFATHER	+	ND		UNKNOWN		YES
31	F	27	YES	HEMODIALYSIS	11	ALIVE	BROTHER	+	ND		GESF		YES
32	F	44	YES	HEMODIALYSIS	22	ALIVE	FATHER/ MOTHER	+	+		UNKNOWN		YES

^aAll patients were hospitalized in Kidney and Hypertension Hospital, São Paulo, Brazil. Na, not applicable. ND, not determined.

GESF, Glomerulonephritis focal segmental scleroderma.

Figure 1. Blood cell counts in the study patients. Leukocyte and lymphocyte cell counts (µL) in the 23 patients before (within 24 hour) and after (60 days) renal transplantation. The values are given as mean ± standard deviation

Figure 2. Status of polyomavirus miRNA-5p in saliva and plasma samples from the study patients. (A-C). Positivity for polyomavirus miRNA-5p and copy number (ml) observed in paired saliva and plasma samples before (within 24 hours) renal transplantation. (B-D) Positivity for polyomavirus miRNA-5p and copy number (ml) observed in paired saliva and plasma samples after (60 days) renal transplantation. In B and D the values are given as mean ± standard deviation. P-values (P < 0.01 and P < 0.05, chi-square test) are given

Figure 3. Comparison of polyomavirus microRNA-5p in study patients before and after renal transplantation. (A-B) Positivity for polyomavirus miRNA-5p and copy number/ml observed in saliva samples before (within 24 h) and after (60 days) renal transplantation. (C-D) Positivity for polyomavirus miRNA-5p and copy number/ml observed in plasma samples before (within 24 h) and after (60 days) renal transplantation. In B and D the values given are the means ± standard deviation